

S4 Table. Univariate analysis for local failure-free survival in the oligometastasis group (n=54) and the oligoprogression group (n=122)

Variable	Oligometastasis group		Oligoprogression group	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Sex (female vs. male)	0.71 (0.17-2.97)	0.634	0.76 (0.35-1.63)	0.474
Age (\geq 60 yr vs. < 60 yr)	0.47 (0.12-1.91)	0.294	1.00 (0.96-1.04)	0.983
EGFR (positive vs. negative)	0.73 (0.18-2.96)	0.659	0.62 (0.29-1.36)	0.236
ALK (positive vs. negative)	0.85 (0.10-7.13)	0.884	2.17 (0.65-7.26)	0.207
ROS1 (positive vs. negative)	0.04 (0.00-84.56)	0.402	0.62 (0.08-4.57)	0.637
PD-L1 (positive vs. negative)	1.24 (0.29-5.31)	0.775	0.66 (0.28-1.51)	0.322
Number of metastatic lesions (per 1 lesion)	1.39 (0.52-3.75)	0.515	0.81 (0.42-1.55)	0.517
Systemic therapy (TKI vs. no TKI)	2.78 (0.56-13.87)	0.214	1.55 (0.72-3.36)	0.268
RT site (bone vs. others)	1.51 (0.36-6.34)	0.573	0.68 (0.27-1.69)	0.408
EQD2 (\geq 43.9 Gy vs. < 43.9 Gy)	2.94 (0.59-14.61)	0.189	1.91 (0.85-4.30)	0.119

ALK, anaplastic lymphoma receptor tyrosine kinase; CI, confidence interval; EGFR, epidermal growth factor receptor; EQD2, equivalent doses in 2 Gy fractions; HR, hazard ratio; PD-L1, programmed death-ligand 1; ROS1, c-ros oncogene 1; RT, radiotherapy; TKI, tyrosine kinase inhibitor.